雷替曲塞联合腹腔镜肝切除术对原发性肝癌患者肝功能及CIART、AFP-L3、GP73的影响

doi:10.12092/j.issn.1009-2501.2020.07.006

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (7): 752-756.doi: 10.12092/j.issn.1009-2501.2020.07.006

雷替曲塞联合腹腔镜肝切除术对原发性肝癌患者肝功能及CIART、AFP-L3、GP73的影响

王高卿^1,2，江伟¹，华永飞¹

¹宁波市医疗中心李惠利医院肝胆外科，宁波 315060，浙江； ²台北医学大学宁波医疗中心，宁波 315060，浙江

收稿日期:2019-09-11 修回日期:2020-06-19 出版日期:2020-07-26 发布日期:2020-07-31
作者简介:王高卿，男，硕士研究生，副主任医师，研究方向：肝胆外科方向。 Tel: 0574-55835583 E-mail: wanglibucx@126.com
基金资助:
浙江省医学会临床科研基金项目（2015ZYC-A50）

Curative efficacy of retetrexel combined with laparoscopic hepatectomy in treatment of patients with primary liver cancer and its effects on liver function and CIART, AFP-L3 and GP73

WANG Gaoqing ^1,2, JIANG Wei¹, HUA Yongfei ¹

¹ Department of Hepatobiliary Surgery, Ningbo Medical Center Li Huili Hospital, Ningbo 315060, Zhejiang, China; ² Ningbo Medical Center, Taipei Medical University, Ningbo 315060, Zhejiang, China

Received:2019-09-11 Revised:2020-06-19 Online:2020-07-26 Published:2020-07-31

摘要/Abstract

摘要： 目的：探讨雷替曲塞联合腹腔镜肝切除术对原发性肝癌患者肝功能及昼夜相关转录抑制因子（CIART）、胎蛋白异质体（AFP-L3）、高尔基体膜蛋白-73（GP73）的影响。方法：选择2012年7月到2019年7月于宁波市医疗中心李惠利医院肝胆外科进行治疗的原发性肝癌患者100例作为研究对象，采用简单随机分组法根据入院顺序分为观察组（n=52）和对照组（n=48），对照组使用腹腔镜肝切除术治疗，观察组在对照组的基础上加用雷替曲塞进行治疗。比较两组的治疗前及治疗后血清CIART、AFP-L3、GP73、谷丙转氨酶（ALT）、谷草转氨酶（AST）、总胆红素（TBIL）水平、1年、3年和5年肿瘤复发率及不良反应发生情况。结果：治疗前，两组患者CIART、AFP-L3、GP73、ALT、AST及TBIL水平水平无显著性差异；治疗后，两组患者血清CIART、AFP-L3、GP73水平均较治疗前显著下降，且观察组患者血清CIART、AFP-L3、GP73水平显著低于对照组（P<0.05）；两组患者血清ALT、AST及TBIL水平无明显差异（P>0.05）。观察组患者5年复发率明显低于对照组，差异有统计学意义（P<0.05）；两组患者1年和3年复发率差异无统计学意义（P>0.05）。两组患者不良反应总发生率分别为53.84%、52.08%，差异无统计学意义（P>0.05）。结论：腹腔镜切除联合雷替曲塞治疗原发性肝癌，可有效降低CIART、AFP-L3、GP73水平，且具有安全性。

关键词: 雷替曲塞, 腹腔镜肝切除术, 原发性肝癌, 肝功能, 昼夜相关转录抑制因子, 胎蛋白异质体, 高尔基体膜蛋白-73

Abstract: AIM: To study the curative efficacy of retetrexel combined with laparoscopic hepatectomy in treatment of patients with primary liver cancer and its effects on liver function and the effects of diurnal transcription suppressor (CIART), fetoprotein heterosomes (AFP-l3), golgi membrane protein-73 (GP73). METHODS: A total of 100 patients with primary liver cancer who were treated in our hospital from July 2012 to July 2019 were selected as study subjects, the patients were divided into observation group (n=52) and control group (n=48) according to the order of admission. The control group was treated with laparoscopic hepatectomy, and the observation group was treated with retetroxel on the basis of the control group. Serum CIART, AFP-L3, GP73, ALT, AST, TBIL, 1-year, 3-year, 5-year tumor recurrence rates and adverse reactions were compared between the two groups before and after treatment. RESULTS:Before treatment, CIART, AFP-L3, GP73, ALT, AST and TBIL levels were not significantly different between the two groups. After treatment, the levels of CIART, AFP-L3 and GP73 in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in serum ALT, AST and TBIL levels between the two groups (P>0.05). The 5-year recurrence rate in the observation group was significantly lower than that in the control group (P<0.05). There was no significant difference in the 1-year and 3-year recurrence rates between the two groups (P>0.05). The total incidence of adverse reactions in the two groups was 53.84% and 52.08%, respectively, with no significant difference (P>0.05). CONCLUSION:Laparoscopic resection combined with letetrexed in the treatment of primary liver cancer can effectively reduce the level of ciart, AFP-L3 and GP73, and it is safe.

Key words: retitrix, laparoscope, hepatectomy, primary liver cancer, liver function, diurnal transcription repressor, fetal protein heterosomes, golgi membrane protein-73

中图分类号:

R979.1

王高卿, 江伟, 华永飞. 雷替曲塞联合腹腔镜肝切除术对原发性肝癌患者肝功能及CIART、AFP-L3、GP73的影响[J]. 中国临床药理学与治疗学, 2020, 25(7): 752-756.

WANG Gaoqing, JIANG Wei, HUA Yongfei. Curative efficacy of retetrexel combined with laparoscopic hepatectomy in treatment of patients with primary liver cancer and its effects on liver function and CIART, AFP-L3 and GP73[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 752-756.

[1]	石丹丹, 孙祎尧, 陈晓琦, 杨芳明, 张传雷, 王新亭, 袁长威, 陈欣菊. 扶正消瘤颗粒治疗原发性肝癌的疗效观察及血清代谢组学分析[J]. 中国临床药理学与治疗学, 2023, 28(11): 1247-1262.
[2]	杜文鹏, 敖检根, 陶祎, 吴观胜, 何佳珂. 自身免疫疾病患者他克莫司稳态血药浓度影响因素的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 645-651.
[3]	郭明星, 郭恒, 沈素, 孙丽莹, 崔向丽. 肝功能不全患者伏立康唑血药浓度监测回顾性研究[J]. 中国临床药理学与治疗学, 2020, 25(7): 757-763.
[4]	毛云，张兆瑞. 人参皂苷诱导骨髓间充质干细胞对急性肝功能衰竭大鼠肝组织再生及Wnt/β-catenin信号表达的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 503-510.
[5]	赵全凤，符佩姝，马欢，赵粟裕，郭代红，唐敏. 伏立康唑所致肝功能损害的主动监测研究[J]. 中国临床药理学与治疗学, 2019, 24(1): 43-48.
[6]	赵鹏程，徐丽丽，李艳玲. 右美托咪定联合靶控输注丙泊酚在肝癌射频消融治疗中的临床效果[J]. 中国临床药理学与治疗学, 2018, 23(6): 682-687.
[7]	喻君，金孝岠，郭建荣，鲁美静，曹亚，常燕. 不同血液稀释法对老年肝癌手术患者凝血及肝脏功能的影响[J]. 中国临床药理学与治疗学, 2018, 23(3): 308-312.
[8]	张洋，陈志康，郭雄，王雯. 雷替曲塞用于腹腔镜结直肠癌根治术中腹腔灌注化疗的安全性研究[J]. 中国临床药理学与治疗学, 2018, 23(3): 313-318.
[9]	袁刚，胡爱荣，胡耀仁，曾传莉，朱德东，石小军. 恩替卡韦和阿德福韦酯治疗代偿期乙肝肝硬化临床疗效及远期预后[J]. 中国临床药理学与治疗学, 2018, 23(2): 170-174.
[10]	张文喜，高未，赵佳佳，蔡俏，赵蓓，郑妍. 红霉素对解脲支原体肺炎的疗效及对细胞亚群和肝功能的影响[J]. 中国临床药理学与治疗学, 2018, 23(2): 194-198.
[11]	赵鹏程，张超. 七氟醚联合丙泊酚对肝硬化患者术后肝肾功能及免疫功能的影响[J]. 中国临床药理学与治疗学, 2018, 23(11): 1276-1281.
[12]	何扬彪，袁春樱，史国军. 膈下逐瘀汤对瘀血内结型肝癌术后血凝状态与生存质量的影响[J]. 中国临床药理学与治疗学, 2017, 22(9): 1056-1061.
[13]	李芸，李兵胜，张卫芳，李义秀，李春，彭娟，赖鑫，朱静，徐睿来，熊爱珍. miR-146a G>C基因多态性与中国原发性肝癌患者遗传易感性的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(7): 779-786.
[14]	胡明华，马晨阳，陈琳，王小明，孙卫东. 吲哚菁绿清除实验在恶性阻塞性黄疸患者术前的应用[J]. 中国临床药理学与治疗学, 2016, 21(5): 543-547.
[15]	何杨, 彭玉珍, 吉兆宁. 雷替曲塞或5-氟尿嘧啶联合奥沙利铂一线治疗晚期胃癌的对比性研究[J]. 中国临床药理学与治疗学, 2015, 20(2): 194-198.

雷替曲塞联合腹腔镜肝切除术对原发性肝癌患者肝功能及CIART、AFP-L3、GP73的影响

Curative efficacy of retetrexel combined with laparoscopic hepatectomy in treatment of patients with primary liver cancer and its effects on liver function and CIART, AFP-L3 and GP73

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价